Type 2 Diabetes Mellitus diabetes complications
Conditions
Interventions
Group Intervention: Individual Empowerment pharmacotherapy (EIEF). 46 participants. Three meetings with the pharmaceutical, 1st meeting: presentation of the project, informed consent signature, applic
Identification of priority to be worked. After 30 days - 3 - selection of an activity, task or action to establish a goal. After 120 days it happens the 4th meeting to evaluate the results and guideli
Drug
Other
N03.219.390
Sponsors
Universidade Federal São João Del-Rei
Universidade Federal São João Del-Rei
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Group Intervention: Patients with DM2 registered HIPERDIA. Aged 18 years. Both sexos.Residentes in the areas of coverage of ESFs belonging to the study. Graduates of EIEF. Low and moderate cardiovascular risk, according to the Framingham score. Control Group: Patients with DM2 registered HIPERDIA. Age less than 18. Both sexes. Residents in the areas covered by ESFs belonging to the study. No participant in any meeting of EIEF. Low and moderate cardiovascular risk, according to the Framingham score.
Exclusion criteria
Exclusion criteria: Group Intervention: Participants from other intervention projects related to DM. reduced cognitive ability, classified by the team of the FHS, as unable to reproduce the transferred information. Control Group:Indivíduos participants from other intervention projects related to DM. Patients with reduced cognitive ability, classified by the ESF team, as unable to reproduce the transferred information. Patients without result HbA1c in the reference period for data collection the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VVariation of 0.67 in mean glycated hemoglobin , comparing the beginning and end of the study , verified by conducting the laboratory examination . | — |
Secondary
| Measure | Time frame |
|---|---|
| Cost-effectiveness analysis : total annual cost of each group ( currency ) divided by the change in HbA1c ( observed benefit) , measured at the beginning and end of the intervention , through consultation of the computerized system (cost) and laboratory test (HbA1c );Reason Incremental Cost-Effectiveness : Cost difference between the intervention and control groups divided by the difference of change in HbA1c between the intervention and control groups, measured at the beginning and end of the intervention , through consultation of the computerized system (cost) and laboratory examination (HbA1c).;Markov modeling: Patients will be allocated according to the Markov health status (healthy, stable, blindness and death). Each of these branches node has a probability weight ranging between 0 and 1. It is then held Markov modeling ten cycles, each cycle corresponding to a year. Thus, you can estimate the number of patients who could develop any complications related to DM2 the end of ten years. The terminal node death will also be possible to estimate the number of years of life were saved by the intervention. | — |
Countries
Brazil
Contacts
Public ContactAna Carolina Gonçalves
Universidade Federal São João Del-Rei
Outcome results
None listed